Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 4/20 | 0.55 |
| ▸ | PRMT6 | Q96LA8 | 4/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057689 | 0.88 | HRH3 (0.57) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL21652009 | 0.84 | CARM1 (0.53) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL18615751 | 0.82 | HRH3 (0.51) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL21779383 | 0.82 | HRH3 (0.51) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL20148064 | 0.79 | DRD4 (0.50) | HRH3SIGMAR1 | |
| SCHEMBL5140977 | 0.79 | CARM1 (0.66) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL26027597 | 0.79 | CARM1 (0.62) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL23972324 | 0.76 | CARM1 (0.67) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL6469380 | 0.76 | OPRM1 (0.59) | CARM1PRMT6HRH3PRMT8TMEM97 | |
| SCHEMBL11210636 | 0.76 | CARM1 (0.57) | CARM1PRMT6HRH3PRMT8TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CARM1 150/4885PRMT6 133/4885HRH3 1000/4885 |
| US-10172845-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | CARM1 150/4885PRMT6 133/4885HRH3 1000/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CARM1 150/4885PRMT6 133/4885HRH3 1000/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | CARM1 150/4885PRMT6 133/4885HRH3 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.